

Index

- abstract thinking, assessment of 15
- academic achievement
 - assessment of 71
 - children with NF-1 221, 223–24
 - diagnosis relating to 8
 - HSCT (hematopoietic stem cell transplantation)
 - children 232
 - importance of early intervention 74–75
 - reduced following radiation therapy 204
 - tests measuring 62
- acute lymphoblastic leukemia (ALL)
 - incidence of 57–58
 - neuropsychological deficits 58–60
 - survival rates 57
 - treatment 58
 - effect on child's development 58
 - MRI studies 23–24
- adaptive functioning 67, 71–73, 205
- adrenocorticotrophic hormone (ACTH) 251, 273
- affective distress and cognitive performance
 - 51–52
- Alzheimer's disease
 - cognitive rehabilitation 285
 - external memory aids 286
 - versus mental stimulation 286
 - donepezil, effectiveness of 177
 - and low testosterone levels 117–18
 - memantine 178–79
 - susceptibility to 117
- androgens
 - androgen deprivation therapy 126–35
 - androgen substitution therapy 118
 - anti-androgens 120
 - effect on spatial abilities 116–18, 125
 - intermittent androgen suppression (IAS) 120

- anemia and cognition
 in cancer patients 51, 102
 hematological cancer patients 232–33
 in non-cancer patients 233
 children and infants 233
- animal models 270, 276
 associated with cancer cells 271–72
 attention deficit hyperactivity disorder (ADHD) 271
 cognitive tests 274–75
 criteria for 271
 distinction from animal tests 270
 fatigue tests 275–76
 laboratory studies, radiation-induced CNS injury 87–88
 models of depression and stress 272–73
 and NF-I gene 215, 217, 224
 olfactory bulbectomy model of depression 271
 rationale for using and problems with 270–71
 tests of depression 273–74
- anti-epileptic drugs, negative effect on cognitive functions
 51, 151, 177
- anti-Hu antibodies 244–46
- anti-VGKC antibodies 246–47
- antidepressant treatments 266, 274, 298
- antineoplastic therapies and cognitive impairment 264
- antineuronal antibodies, paraneoplastic limbic
 encephalitis (PLE) patients 240–41, 244–47
- antipsychotic drugs for delirium 262
- anxiety, effect on cognitive performance 51–52, 263
- apoptosis, effects of abnormal signaling 214–15
- aqueductal stenosis 215
- aromatase inhibitors, breast cancer 119, 126
- assessment *see* neuropsychological assessment
- astrocytes 84
- astrocytomas 143, 216
- attention
 assessment of 12–13, 62, 68–69, 74
 effect of anemia 233
 effect of radiation therapy on sustained 204–5
 remediation programs for 73–74, 287, 307
 strategy training for deficits in 283–84
 and working memory 69
- attention deficit hyperactivity disorder (ADHD) 215, 271
- Attention Process Training (APT) technique 73–74, 287
- autoimmunity
 children with paraneoplastic opsoclonus-myoclonus
 250–51
 patients with paraneoplastic limbic encephalitis 244–47
 theory of 239–40
see also immunotherapy
- Beck Depression Inventory II (BDI-II) 296
- behavioral intervention strategies 281–82
 degenerative conditions 285–87
 traumatic brain injury (TBI) 281, 283
 attention deficits, strategy training for 283–84
 memory and learning deficits, strategy training for
 284–85
 problem solving for executive function deficits
 285
- benzodiazepines (BZPs) 262–63
- biological response modifiers (BRMs) 106
see also interferon alpha (IFN- α)
- brain edema
 executive function deficits 174
 pharmacological interventions 35, 314–16
 symptoms of 175
- brain metastases 170
 clinical presentation 171
 cognitive sequelae of cancer therapy 175
 adjuvant medications 177
 radiotherapy 175
 surgery 176
 systemic anticancer therapy 176
- diagnosis and treatment in children 58
- effect of motexafin gadolinium 322
- epidemiology 170–71
- neurocognitive impairment 173
 due to cancer 174–75
 etiology and pathogenesis 174
 incidence of 173–74
 management of 177; donepezil 177–78; hyperbaric
 oxygen 178; methylphenidate 177; NMDA receptor
 178–79; transplantation of purified
 oligodendrocytes 178
 prevention of; avoidance of hippocampus in
 whole-brain radiation therapy 180–81;
 erythropoietin (EPO) 180; radiation dose and
 fractionation 179; radiosurgery alone 179–80
- prognosis 171
- risk of developing 34
- treatment 171–73
- brain structure and function
 impact of disease, genetics and therapies
 104–6
 nervous system development 56–57
- brain tumors
 growth rate 35
 location and size of
 and degree of deficits 34–35, 174, 203

- and presenting symptoms 34
- and psychiatric symptoms 37
- neurofibromatosis NF-1 215–17
- symptoms/symptom clusters 312, 314
- see also* childhood brain tumors; high-grade gliomas; low-grade gliomas
- breast cancer
 - and chemotherapy 36
 - MRI studies of cognitive changes 25–28, 104
 - and hormonal therapy 119
 - impact on cognitive function 120–26
- cardiac complications of childhood cancer survivors 199–200
- central nervous system (CNS)
 - disease, assessment of patients with 48–49
 - radiation-induced toxicities 91
 - see also* nervous system; radiation-induced CNS injury
- cerebral vascular accident (CVA), behavioral intervention strategies for 283–85
- “chemobrain”/“chemofog” 49–50
 - in children 98
 - patient-reported 98–99
 - retrospective studies 98
 - symptoms of 97–98
- chemotherapy
 - for brain metastases 173
 - chemotherapeutic agents
 - neurotoxicities associated with 50, 99; risk factors underlying 99–103
 - and cognitive dysfunction 49–50, 97, 176
 - etiological mechanisms underlying 176
 - hematological malignancies 230–31
 - incidence and nature of 97–99
 - neuroimaging and EEG studies 103–4
 - pharmacogenetic modulation of 104–6
 - high-dose methotrexate for primary central nervous system lymphoma 188–89
 - intrathecal methotrexate, effects on children 59
 - for low-grade gliomas 147, 151
 - neurocognitive changes following
 - risk factors implicated in 20
 - studies demonstrating 19–20
 - neuroimaging of cognitive changes 19, 23
 - breast cancer patients 25–28
 - childhood leukemia treated without radiation therapy 23–24
 - leukoencephalopathy in adults 25
 - osteosarcoma patients treated with high-dose methotrexate 24–25
- childhood brain tumors 58, 198
 - lifelong annual medical follow-up 206
 - medical late effects 198–99
 - cardiac complications 199–200
 - endocrine complications 200–1
 - gastrointestinal and hepatic complications 201–2
 - hearing and sight disorders 201
 - neurological complications 200
 - pulmonary complications 200
 - renal complications 201
 - secondary malignancies 199
 - neuropsychological late effects 202
 - neurocognitive late effects 202–5
 - psychosocial late effects 205–6
 - treatment and rehabilitation 206
- childhood cancer
 - assessment *see* neuropsychological assessment, children
 - behavioral interventions 73–74
 - common forms of 57–58
 - acute lymphoblastic leukemia (ALL) 23–24, 58
 - brain tumors *see* childhood brain tumors
 - increase in survival rates 57
 - neuropsychological deficits 58–59
 - children treated for ALL 59–60
 - children with brain tumors 202–6
 - school and educational support 301–2
 - support for parents 303
 - see also* paraneoplastic opsoclonus-myoclonus (POM)
- childhood leukemia *see* acute lymphoblastic leukemia (ALL)
- Children’s Oncology Group (COG)
 - neuropsychological test battery 72–73
 - screening guidelines 206
- ciclosporin 229
- cisplatin
 - and hearing loss in children 70, 201
 - nephrotoxic effects of 201
 - and osteosarcoma 25
- clinical neuropsychology 6
 - assessment goals 8–10
 - assessment tests 12–16
 - historical background 7–8, 56
 - standard evaluation procedures 10–12
 - see also* neuropsychological assessment
- clinical trial endpoints 4, 40, 45, 48, 162, 320, 327
- clinical trials *see* neurocognitive testing

- cognitive dysfunction
 in adult cancer patients 33
 due to tumor progression in high-grade glioma 160
 paucity of research 33
 in brain metastases patients 173–74
 deficits due to cancer 174–75
 correlation to caregiver burden 39
 due to antineoplastic therapies 264
 IFN- α causing 107–8
 late delayed effect of radiation therapy 316
 in pediatric brain tumors, late effects 202–5
 potential causes of 4
 predictors of 4
 symptoms and effects of 3–4
- cognitive function
 assessment of 4
 for descriptive reports 8–9
 following surgery 9
 goals of 8–10
 reasons for referral 9–10
 serial assessments 9
see also neuropsychological assessment
- role of reproductive hormones 115–16
 androgen substitution therapy 118
 estrogen in women 103, 116
 hormone replacement therapy (HRT), studies of 116
 testosterone in men 117–18
- cognitive rehabilitation 281–82
 cancer patients 287, 307
 adults with primary brain tumors 287–88, 307
 clinical application 289; guided questions 290–91;
 selecting appropriate intervention 289–91; timing
 of intervention 291
 Cognitive Remediation Program (CRP) 287
 low referrals for rehabilitation 287
 problem-solving therapy 288, 291–93
 and randomized controlled trials 289
 research questions 288–89
 definition of 282–83
 degenerative conditions 285
 cognitive rehabilitation versus mental stimulation 286
 external memory aids 286
 strategies for acquired brain injury
 Cicerone recommendations 283
 strategy training 282
 attention deficits 283–84
 executive function deficits 285
 external and internal procedures 282–83
 memory and learning deficits 284–85
 Cognitive Remediation Program (CRP) 73–74, 287
 cognitive set shifting, assessment of 15–16
 community re-integration 301
 complementary and alternative medicine 307–8
 computerized axial tomography (CAT) 20–21
 low-grade gliomas 144
 in osteosarcoma 24
 patients with paraneoplastic limbic encephalitis 248
- core cognitive processes
 assessment of 68
 attention 68–69
 processing speed 69
 working memory 69
 deficits in children
 treated for ALL 59–60
 treated for brain tumor 204–5
- corticosteroids 25, 36, 160, 251
- counseling 304
- cranial radiation therapy
 childhood brain tumors
 age risk factor 203
 brain injury caused by 203
 cognitive deficits caused 203
 impact on attention, processing speed and working
 memory 204–5
 impact on global IQ 203–4
 impact on non-dominant hemisphere processes 204
 neuropsychological outcome of 59
 treatment of optic glioma 216–17
see also radiation therapy (RT)
- cytokines
 and immune response 233–34
 indirect effects on CNS function 176
 neurotoxic side-effects of 50
 pro-inflammatory activity of 103, 105
see also interferon alpha (IFN- α)
- data collection, test administration 324
- delirium
 assessment of 260
 EEG and neuroimaging 262
 laboratory assessment 261–62
 rating scales 261
 classification of 259
 common causes of in cancer patients 260
 definition and classification of 258–59
 management of 262–63
 in palliative care settings 264–65
 risk factors 259–60

- dementia
 cognitive rehabilitation 286–87
 and complementary and alternative therapies 308
 depression dementia/pseudodementia 263
 evaluation to rule out 46–47
 and hormone replacement therapy (HRT) studies 116
 screening tools 162
 and whole-brain radiation therapy 173, 175
- demyelination, radiation-induced 84, 148, 188
- depression 37, 298
 animal models of 272–73
 animal tests of 273–74
 Beck Depression Inventory II (BDI-II) 296
 differentiating from neurocognitive impairment 37
 effect on cognitive performance 51–52
 major depression in cancer survivors 263
 side-effect of interferon treatment 107
- dexamethasone 87, 314–16
- differential diagnosis 8, 40
 patients with suspected paraneoplastic limbic encephalitis 247
 of seizures in cancer patients 161
- diffusion tensor imaging (DTI) 22
- Distress Thermometer and Problem List 296–97
- donepezil
 Alzheimer's disease 177
 for fatigue and sedation 266
 late radiation-induced brain injury 317
 lung cancer patients 177–78
 trials for brain tumors/metastasis 164, 178
- Drosophila* NF-I protein 217
- dyslexia, MRI studies 215, 223–24
- edema *see* brain edema
- electroencephalography (EEG) 104, 244, 262
- embryogenesis, impact of NF-I gene 214–16
- emotional functioning
 assessment of in children 71–72
 demoralization and distress 298–99
 psychiatric medications 234
 support services 297–99
see also anxiety; depression; mood
- employment
 return to work 46, 299
 support needed in work settings 302
 vocational status of children with cancer 205
- encephalopathy
 chemotherapeutic agents associated with 99–100, 102–3
 following radiotherapy 148–50, 175
 hematological cancer patients 229
 and high-dose methotrexate treatment 24
 methotrexate-induced 229
see also leukoencephalopathy; paraneoplastic disorders
- endocrine complications in long-term survivors of
 childhood brain tumors 200–1
- epidemiology
 brain metastases 170–71
 low-grade gliomas 142–43
 secondary malignancies 199
- epileptic seizures *see* seizures
- erythropoietin (EPO), brain metastases 180
- estrogen 115
 aromatase inhibitors, impact of 119, 126
 effect on cognitive function 103, 116–17, 126–35, 176
 estradiol therapy for prostate cancer 136
 luteinizing-hormone-releasing hormone (LHRH)
 suppressing production of 119
see also tamoxifen (TAM)
- European Organization for Research and Treatment of
 Cancer QLQ-C30 (EORTC) 38, 48, 91, 146, 158, 163
- executive function (EF) 69
 assessment of 15–16
 in children 66, 69–70
 sample tests for 62
 compensation-oriented cognitive rehabilitation 289–91
 impairment of
 following IFN- α treatment 232
 formal problem-solving strategies for 285
 improved with *Ginkgo biloba* 317
 rehabilitation strategies 307
- experimental neuropsychology 6
- external radiation therapy (XRT) 36–37
- eye, formation of 215–16
- family caregivers
 factors predicting improvement in children with brain tumors 205–6
 quality of life (QOL) benefits of neuropsychological assessment 38–40
 support for 302–3
- farnesyltransferase inhibitors 213–14, 217
- fatigue 51, 295
 animal models and tests 275–76
 associated with anemia 232–33
 complementary and alternative medicine therapies for 307–8
 pharmacological interventions 266, 312–13

- fatigue (*cont.*)
 and return to normal functioning 299
 side-effect of interferon treatment 107, 232
- Food and Drug Administration (FDA) 40, 45, 48, 320
- Functional Assessment of Cancer Therapy (FACT) 48, 313, 317
- functional MRI (fMRI) 22–23
 breast cancer survivors 26–27, 104
 high-grade gliomas (HGG) 160
 neurofibromatosis (NF-I) studies 222–23
 reading and visual-spatial processing 223
- genetics
 animal studies and NF-I gene 215, 217, 224
 low-grade gliomas 143–44
 polymorphisms of genes and cognitive function 104–7
- gliomas *see* high-grade gliomas; low-grade gliomas
- glucocorticoids 35, 177, 273
- gray matter (GM)
 volume increase in NF-I patients 222
 volume loss following chemotherapy 26–27, 103
- growth mixture modeling 327
- hair loss following radiation therapy 313
 effects on cognition
 prospective studies 190–91
 retrospective studies 191–93
 interactions with whole-brain radiation therapy 188–89
 and white matter abnormalities 193–94
- hearing loss in childhood tumor survivors 201
- hematological malignancies 228
 cognitive deficits 229
 due to anemia and iron deficiency 232–33
 immune response mechanisms 233–34
 treatment effects 229–30; biological response
 modifiers 232; chemotherapy 230–31;
 hematopoietic stem cell transplantation (HSCT)
 231–32; radiation therapy 231
 neurological complications of 228–29
 treatment for cognitive and emotional dysfunction 234
- hematopoietic stem cell transplantation (HSCT) 231–32
 effects on neuropsychological functioning 230, 232
 neurological complications 228–29
- high-dose-methotrexate-based chemotherapy for primary
 central nervous system lymphoma 187–88
- high-grade gliomas (HGG) 156
 nervous system problems 158
 neurocognitive assessment 162
 importance of 162–63
- neurocognitive deficits
 causes of 158–62
 cognitive rehabilitation 165
 prevention of 164–65
 treatment of 163–64
 and survival 156–58, 163
- hippocampus
 avoidance of during whole-brain radiation therapy
 180–81
 hippocampal neurogenesis 85–86, 103, 164
 history of neuropsychology 7–8, 56
- hormonal deficiencies in long-term survivors of childhood
 brain tumors 200–1
- hormonal therapy 115
 in cancer treatment 119, 176
 breast cancer 119; influence on cognitive functioning
 50, 120–26
 factors to include in studies 138
 prostate cancer 119–20; influence on cognitive
 functioning 50, 126–35
- hormone replacement therapy (HRT)
 dementia studies 116
 for growth hormone deficiency 201
- methodological aspects 136
 cross-sectional versus prospective studies 136
 group means comparison versus individual test score
 analysis 137
 mood and psychosocial factors 137
 sample size 136
 selection of cognitive tests 137
 self-reported cognitive problems 137
 neuroimaging studies 118
 reproductive hormones and cognition 115–18
- hospice agencies and quality of life 300
- hyperactive delirium 259–60, 262
- hyperbaric oxygen (HBO)
 myelopathy prevention, animal studies 87
 treatment for brain metastasis 178
- hypoactive delirium 259, 262–63, 266, 300
- IFN- α *see* interferon alpha
- immune response mechanisms 233–34
- immunotherapy
 biological response modifiers (BRMs) 106
 impact on cognitive function 50
 for paraneoplastic disorders 241
 factors influencing response to 241–42
 poor prognosis for neurological improvement
 242

- response of patients with paraneoplastic limbic encephalitis 248–49
- individual psychotherapy 304
- indomethacin, preventative trials 164
- intellectual functioning
- children with NF-I 217–18
 - clinical tests of intelligence 12, 62
 - global IQ 66–67, 203–4
 - impact of cranial radiation therapy on children 59, 202–5
 - impact of intrathecal methotrexate 59, 231
 - see also* academic achievement; core cognitive processes
- interferon alpha (IFN- α) 106–7
- animal studies of fatigue 276
 - and cognitive impairment 107–8, 232
 - mechanisms underlying 108–9
 - side-effects of 107
 - interventions for 109
- intrathecal methotrexate, effects of treating children with 59, 231
- iron deficiency, effects of 232–33
- irradiation *see* cranial radiation therapy; radiation therapy (RT)
- Judgment of Line Orientation (JLO) test 219–20
- language
- assessment of 14, 62, 70, 74
 - critical period for development of 56
 - see also* reading problems in NF-I children
- learned helplessness, animal stress models 273
- learning disability (LD), children with NF-I 212, 217–19
- learning and memory
- animal tests 274–75
 - assessment children 62, 67–68
 - strategies for Alzheimer's disease 286
 - see also* memory
- leukoencephalopathy
- in adults, chemotherapy-induced 25
 - chemotherapeutic agents associated with 99, 189
 - following high-dose methotrexate treatment 24
- limbic encephalitis *see* paraneoplastic limbic encephalitis
- low-grade gliomas (LGG) 142
- clinical features 144
 - epidemiology and biology 142–43
 - genetics 143–44
 - imaging features 144
 - neurocognitive deficits, factors causing 147
 - medical therapy 151
 - mood disorder 151
 - primary tumor 147–48
 - radiation 148–50
 - surgery 148
 - pathology 143
 - prognostic factors 144–45
 - therapeutic management
 - chemotherapy 147, 151
 - radiotherapy 146–47
 - surgery 145–46
- luteinizing-hormone-releasing hormone (LHRH) agonists 119
- impact on women 120
 - prostate cancer treatment 50
 - impact on cognitive functioning 126, 135, 176
 - prevention of tumor flare with anti-androgens 120
- macrocephaly in patients with NF-I 222
- magnetic resonance imaging (MRI) 20
- and CNS tumors 320
 - dyslexia/reading-disabled patients 215
 - effects of tamoxifen on hippocampal atrophy 125
 - leukoencephalopathy in adults 25
 - low-grade gliomas (LGG) 144, 146
 - MR hyperintensities in children with NF-I 221–22
 - osteosarcoma patients 24–25
 - paraneoplastic limbic encephalitis patients 244
 - primary central nervous system lymphoma patients 189, 194
 - see also* functional MRI (fMRI); positron emission tomography (PET); structural brain imaging methods
- magnetic resonance spectroscopy (MRS) 22
- comparison with MRI in breast cancer patients 28, 34
 - impact of tamoxifen and hormone replacement therapy on brain function 125
- medications
- antidepressants 266, 274, 298
 - antipsychotics for managing delirium 262–63
 - assessment results confounded by 51
 - confounding tumor-related causes of cognitive deficits 160–61
 - delirium-inducing in cancer patients 260
 - symptomatic pharmacotherapy 265–66

- medulloblastomas 57–58, 164
 effect of age at time of cranial radiation therapy 203
 evaluation of 10-year survivors 299
 psychosocial effects of treatment 205
 risk of secondary malignancies 199
 treatment affecting attention, memory and new learning 204–5
- memory
 animal tests 274–75
 assessment of 14–15, 67–68, 74
 effects of androgen deprivation therapy 126, 135
 impairment 3
 in Alzheimer's disease 285
 amnesia in paraneoplastic limbic encephalitis patients 243
 combined modality therapy in patients with primary central nervous system lymphoma 192–93
 due to anxiety and depression 51–52
 following chemotherapy 27–28, 98, 230
 following hormonal therapy 135
 from radiation therapy 49
 hematopoietic stem cell transplantation patients 232
 IFN- α treatment 232
 in patients with delirium 260
 and tamoxifen 120
 processes 15
 rehabilitation
 external memory aids 286
 internal procedures, other regulated 286
 memory notebook 282, 284–85, 288
 using calendar system 291–92
 role of hippocampus 180–81
 role of NMDA receptor 178–79
see also non-verbal memory; verbal memory; working memory
- menopause
 chemotherapy and surgically induced 102, 116
 effect of hormone levels during 116
 hormone replacement therapy (HRT), studies of 116
- mental stimulation tasks for Alzheimer patients 286
- metastatic brain tumors *see* brain metastases
- methotrexate (MTX)
 causing microvascular injury and myeloencephalopathy 103
 for hematological malignancy 229
 intrathecal methotrexate, effects of treating children with 58–59
 leading to metabolic abnormalities 99–102
 for osteosarcoma 24–25
see also high-dose-methotrexate-based chemotherapy for PCNSL
- methylphenidate (Ritalin®) 177
 for attention deficit hyperactivity disorder (ADHD) 271
 for fatigue 313, 316
 high-grade glioma patients 164, 177
 for hypoactive delirium 266, 300
- microglia, impact of irradiation on 84–85
- Mini-Mental State Examination (MMSE) 38, 46, 117, 162, 261, 321
- modafinil 164, 266
- molecular imaging methods 23
- mood
 assessment of 16
 cluster in newly diagnosed brain tumor patients 312
 detrimental effect on test performance 137
 disorders, link to cognitive dysfunction 51–52, 98–99, 151, 263
- motor and sensory-perceptual function, assessment of 16, 62, 71
- myelination 56–57
 demyelination, radiation-induced 84, 91, 148, 188
 remyelination, transplantation of oligodendrocytes 178
- myeloencephalopathy 103
- myoclonic encephalopathy of infancy 249
- nervous system
 development of 56–57
 effects of early brain damage 57
 plasticity of 57
 treatment-related injury, effects on children 58
see also central nervous system (CNS)
- neurocognitive impairment *see* cognitive dysfunction
- neurocognitive testing
 Children's Oncology Group (COG) test battery 72–74
 implementation in clinical trials 323
 data collection 324
 personnel and training needs 323–24
 importance of formal testing 320–21
 Oregon Health Sciences University test battery 73
 statistical and interpretive issues
 analytical approaches; growth mixture modeling 327;
 Q-TWiST methods 327; regression-based methods for predicting change scores 326; reliable change index (RCI) 325–26; repeated measures analyses 327; time to event analyses 326–27
 confounding variables and missing data 324–25

- test selection
 factors influencing; focal versus diffuse function
 321–22; frequency of testing 322; impact of disease
 and treatment 322; psychometric properties 321;
 study design: baseline versus repeated testing 323
see also neuropsychological assessment
- neurodegenerative conditions, cognitive rehabilitation
 285–87, 291
- neurofibromatosis (NF)
 brain structure and function correlates 221
 brain tumors 221
 congenital malformation 222
 macrocephaly 222
 MR hyperintensities 221–22
- children with NF-I 217
 academic achievement of; impact of visual spatial
 abilities 219–21; and learning disability (LD)
 218–19
 intellectual functioning 217–18
 diagnostic criteria 212, 219–21
 functional imaging studies 222–23
 genotype 212–13, 224
 history 211
 phenotype 211–13, 223–24
 Ras signaling system 213, 217
 systemic impact
 benign tumors, focal growth dysregulation in 214
 brain malformations 214–15
 brain tumors 215–17
 farnesyltransferase inhibitors, positive effect on
 learning 217
 on function 217
 role of NF-I gene, animal studies 217
- neurogenesis
 attempts to rectify RT-induced decrease 87, 164
 in hippocampus of rat brain 86
 impact of chemotherapies on 103
 of neural stem cells, effects of radiation 85–86
- neuroimaging technologies 20–23
see also magnetic resonance imaging (MRI)
- neurons
 and neurogenesis 85–87
 rapid growth and pruning 56
 sensitivity to radiation 85
- neuropsychological assessment 44–45
 adult cancer patients 33–34, 44
 benefits for patient's clinical medical management
 34; cancer surveillance 35; depression, effects on
 cognition 37; presenting symptoms and tumor
 location 34–35; prognostic value of assessment
 37–38; side-effects of treatment 35–37
- cancer research benefits 40
 clinician benefits 38
 disease and treatment issues; adjunctive medications
 51; affective distress 51–52; anemia 51; assessment
 of patients with CNS disease 48–49; chemotherapy
 49–50; fatigue 51; hormonal therapies 50;
 immunotherapy 50; radiation therapy 49
- high-grade gliomas 162–63
 principles of assessment 45–46; assessment process
 47; cognitive areas of interest 47–48;
 patient-reported outcomes (PROs) 48; test
 selection 46–47; timing of assessments 47
 quality of life benefits for patient and family
 caregivers 38–40
- children 60
 approaches to assessment 61–66
 areas to evaluate; academic achievement 71; core
 cognitive processes 68–69; executive function (EF)
 69–70; language 70; learning and memory 67–68;
 motor and sensory-perceptual function 71;
 non-verbal skills 70–71; overall intellectual
 functioning 66–67; psychosocial and adaptive
 functioning 71–72
 future directions 75
 liaison with schools 61
 serial assessments 60–61
 test batteries; Children's Oncology Group (COG)
 72–73; Oregon Health Sciences University 73
see also cognitive function, assessment of
 neuropsychology 6
- ecological validity 75
- evaluation
 for descriptive reports 8–9
 following surgery 9
 goals of 8
 reasons for referral 9–10
 serial assessments 9
 standard procedures; clinical interview 10–11;
 dissemination of findings 11–12; history taking 10;
 interpretation of results 11; test administration 11;
 test selection 10
 future directions in 73–75
 history of 7–8, 56
 terminology issues 71
- neurosurgery *see* surgery
- NF-I (neurofibromin-1) *see* neurofibromatosis (NF)
- NMDA (*N*-Methyl-D-aspartate) receptor 178–79

- non-verbal learning disability (NVLD) 218–19
 non-verbal skills, assessment of in children 70–71
 non-verbal memory 14, 59, 68
- object perception, assessment of 13
- oligodendrocytes
 effect of radiation on 84, 91, 188
 oligodendroglioma 144–45, 147
 transplantation of promoting remyelination 178
- onconeural antigens 239–41, 251
- online support groups 306
- opsoclonus-myoclonus *see* paraneoplastic
 opsoclonus-myoclonus (POM)
- optic tumors in neurofibromatosis (NF-1) patients 215–17
- Oregon Health Sciences University test battery 73
- osteosarcoma, neuroimaging studies 24–25
- oxidative stress, radiation-induced 86, 92
- oxygen treatment for brain metastasis 178
- palliative care settings
 hospice agencies 300
 management of delirium 264–65
 symptoms requiring pharmacotherapy 265–66
see also supportive care
- paraneoplastic disorders 239
 antineuronal antibodies 240–41
 and autoimmunity theory 239–40
 clinical importance of 239
 clinical neurological outcome 241
 factors causing neuronal injury 241
 immunotherapy for 241–42
 limbic encephalitis (PLE) 242–43
 autoimmunity 244–47
 clinical features 243–44
 diagnostic studies 244
 differential diagnosis 247
 pathology 243
 patient management 248–49
- opsoclonus-myoclonus (POM)
 autoimmunity 250–51
 clinical features 249–50
 pathology 250
 patient management 251–52
- prognosis for neurological improvement 242
- paraneoplastic limbic encephalitis (PLE) 242–43
 autoimmunity 244–47
 clinical features 243–44
 diagnostic studies 244
 differential diagnosis 247
 management of 248–49
 pathology 243
- paraneoplastic opsoclonus-myoclonus (POM)
 autoimmunity 250–51
 clinical features 249–50
 pathology 250
 patient management 251–52
- parenchymal hypothesis for radiation-induced CNS injury 84
- parents of childhood cancer survivors
 information provision 75
 support for 303
see also family caregivers
- patient-reported outcomes (PROs) 48
- pediatric oncology *see* childhood cancer
- peer support groups 304–6
- personality, assessment of 16
- phonological processing, functional MRI studies 223
- pituitary tumors 200
- planning ability, assessment of 15
- PLE *see* paraneoplastic limbic encephalitis
- polyunsaturated fatty acids, reducing paralysis, animal studies 87
- POM *see* paraneoplastic opsoclonus-myoclonus (POM)
- Porsolt Forced Swim Test, animal test of depression 273–74
- positron emission tomography (PET) 23
 effects of tamoxifen and estrogen on brain glucose metabolism 125
 hippocampal hypermetabolism in patients with paraneoplastic limbic encephalitis 244
 neural effects of chemotherapy in breast cancer patients 27–28
- PPAR γ agonists, role of pioglitazone in reducing inflammation 87–88
- practical needs of cancer patients 299
- practice effects, test administration 9, 60, 136, 323, 325
- primary CNS lymphoma (PCNSL) 187
 cognitive dysfunction 189–90
 prospective studies 190–91
 retrospective studies 191–93
 and treatment-related white matter abnormalities 193–94
 diagnosis 187
 treatment 187–88
 delayed neurotoxicity 188–89
- problem-solving therapy 292–93
 for adults with cancer 288
 for executive functioning deficits 285
 at the Mayo Clinic 288, 291–93

- processing speed
 assessment of 13, 69
 psychometric tests 62
 deficits following cranial radiation therapy 204–5, 230
 effects of hormone therapy 126, 135
 and IFN- α treatment 232
- prophylactic interventions
 for children with cancer 73–75
 prophylactic cranial irradiation (PCI) 36
- prostate cancer, hormonal therapy 119–20
 impact on cognitive function, studies 127
 influence of luteinizing-hormone-releasing hormone agonists 50, 126–36
- psycho-education 296–97, 306
- psychosocial functioning
 assessment of in children 62, 71–72
 late effects, childhood brain tumor survivors 205–6
 measures of 73, 75
- psychosocial interventions 234, 304–6
- pulmonary complications in long-term survivors of childhood brain tumors 200
- Q-TWiST methods 327
- quality of life (QOL) of cancer survivors 156
 assessment feedback helping to maximize 39–40
 clinical trial endpoint 40
 for primary brain tumors 320
 for radiation-induced brain injury 317
 complementary and alternative medicine therapies improving 307–8
 hospice care 300
 importance of multidisciplinary approach to interventions 312
 interventions to improve, symptom-focused 281
 patient-reported outcomes (PROs) 48
 patient's appreciation of 163
 in primary central nervous system lymphoma patients 192
 and problem-solving therapy 288
 psychosocial support 234, 304–6
 relationship to cognitive impairment 38–39
 research on health related 58
 support services improving 296
 tests measuring 73, 159, 296–97
- radiation-induced CNS injury
 indomethacin reversing 86, 164
 laboratory studies of therapeutic interventions 87–88
 oxidative stress 86, 92
- pathogenesis 83, 175
 astrocytes 84
 classical model 83
 contemporary view 86
 microglia 84–85
 neural stem cells and neurogenesis 85–86
 neurons 85
 parenchymal hypothesis 84
 vascular hypothesis 83
- pharmacological interventions for 312
 acute reactions 312–14
 early delayed reactions 314
 late delayed reactions 314–17
- preventative and therapeutic interventions 92
- quantitative scoring of CNS toxicity 90–92
- radiation necrosis 83, 91–92, 202
- radiation tolerance of CNS tissues
 factors associated with 88
 importance of dose and fraction size 90
 mathematical models for tolerance doses 89
 neuret model of brain tolerance 90
see also central nervous system (CNS); radiation therapy (RT)
- Radiation Therapy Oncology Group (RTOG) 91, 149, 171, 174, 179
- radiation therapy (RT) 231
 acute reactions 175, 312–14
 early delayed reactions 91, 175, 314
 endocrinological sequelae 200–1
 focal versus whole brain 149
 late delayed reactions 91, 175, 314–17
 for low-grade gliomas 146–47
 negative effects on cognitive performance 23
 childhood brain tumor patients 203–5
 CNS disease patients 49
 low-grade glioma patients 148–51
- tolerance doses
 for normal CNS tissues 88–89
 for other normal CNS tissues 90
- treatment volumes and doses for brain tumors 313
see also cranial radiation therapy; whole-brain radiation therapy (WBRT)
- radiosensitizers 173
- radiosurgery 172–73, 179–80
- raloxifene 125
- reactive oxygen species (ROS) 85–86
- reading problems in NF-I children 218–19
 functional MRI studies 215, 223
 and malformation in brain regions 222

- Recklinghausen's disease *see* neurofibromatosis (NF)
- regression-based methods for predicting change scores 326
- rehabilitation
 brain tumor patients 165
 children with brain tumors 206
 children with cancer 73–75
see also cognitive rehabilitation; support services
- reliable change index (RCI) 325–26
- renal complications, long-term survivors of childhood brain tumors 201
- repeated measures analyses 327
- reports, neuropsychological evaluations 8–9, 12
- reproductive hormones and cognition 119
 in healthy men 117–18
 in healthy women 116–17
 neuroimaging studies 118
see also hormonal therapy
- response inhibition, assessment of 15
- secondary malignancies 199
- seizures 160
 anti-epileptic drugs, negative effect on cognitive functions 51, 151, 177
 chemotherapeutic agents associated with 100
 differential diagnosis of patients with cancer 161
 effects on cognitive function 151
 in low-grade glioma 144
- selective estrogen receptor modulators (SERMs) *see* raloxifene; tamoxifen
- self-instruction training 285
- sensorimotor ability, assessment of 16, 62
- serial assessments 9, 60–61
- small cell lung carcinoma (SCLC) 239
 antineuronal antibodies associated with and multifocal encephalomyelitis 243–44
 onconeural antigens 241
 presence of anti-Hu antibodies 245–46, 248
 prognosis 242, 248
 prophylactic cranial irradiation (PCI), effects of 36, 173–74
 whole-brain radiation therapy, response to 171
- socialization problems in childhood brain tumor survivors 205–6
- somnolence syndrome 91, 314
- spatial perception
 assessment of 13
 role of androgens 116–18
- special education services 301–2
- statistical methodologies 325–27
- steroids
 for brain edema 314–15
 side-effects 35, 51
 for somnolence syndrome 314
see also corticosteroids; dexamethasone; glucocorticoids
- stress
 animal and human models of 272–73
 and brain norepinephrine (NE) activity 273
 reduction of with complementary and alternative medicine therapies 307–8
 underlying physiology of 273
- structural brain imaging methods 20–22
 analysis of data using voxel-based morphometry 21–22
 in breast cancer patients 25–27
 childhood leukemia studies 23–24
- support services 295–96
 community re-integration 301
 complementary and alternative medicine 307–8
 during active treatment 298–99
 end of life/palliative care 300
 family settings 302–3
 modalities of support 303–4
 needs assessment 296–97
 across the disease continuum 297
 newly diagnosed patients 297
 post-treatment 299–300
 psychosocial support 304–6
 rehabilitation programs 306–7
 school settings 301–2
 work settings 302
- supportive care 258
 drugs used 264
 future research
 detection and screening 266
 treatment of delirium 266
see also delirium
- surgery
 childhood brain tumors 58
 low-grade gliomas 145–46, 148
 neuropsychological evaluation to clarify outcome of 9
 risks of damage to healthy tissues 35
 in treatment of brain metastases 172
 effects on cognition 176
 radiosurgery alone 172–73, 179–80
 radiosurgery with whole-brain radiation therapy 172
- survival
 acute lymphoblastic leukemia (ALL) 57, 228
 childhood brain tumors 198–99

- high-grade gliomas 156–58
 low-grade gliomas 138, 142, 144–45
 predictors of length of 37–38
 primary CNS lymphoma with methotrexate 188
 versus “compression of morbidity” 156, 163
 switching, assessment of 15–16
 symptom management *see* supportive care
 systemic anticancer therapies, effect on brain function
 176
- tail suspension test (TST) 274
- tamoxifen (TAM)
 effects on cerebral metabolism 28
 estrogenic and anti-estrogenic qualities 119
 impact on cognitive function 36, 50
 studies of 120–26
- testosterone levels
 anti-androgens 120
 effect of aromatase inhibitors 119
 effect on cognitive performance 116–18, 126–34
 and visual-spatial abilities 137
see also androgens; luteinizing-hormone-releasing
 hormone (LHRH) agonists
- thyroid gland abnormalities 108–9, 201
- Time Pressure Management (TPM) 283–84
- time to event analyses 326–27
- traumatic brain injury (TBI), cognitive rehabilitation 281,
 283–85
- twin studies, breast cancer and chemotherapy 27
- vascular damage, radiation-induced 83, 202
- verbal memory
 assessment of 14
 influence of high levels of estrogens 116
 influence of hormonal therapy
 in men 126, 135
 in women 120, 126
 tests for measuring in children 62
- visual ability 70–71
 assessment of 13–14
 psychometric tests 62
- visual spatial abilities
 animal studies 217
 and children with non-verbal learning disability 218–19
 functional MRI studies 223
 and reading problems in children with NF-I 219
 tests measuring 74
 tests predicting NF-I diagnosis 219–21
see also spatial perception
 voxel-based morphometry (VBM) 21–22
 breast cancer studies 25–27
- Wake Forest University School of Medicine clinical trials
 316–17
- Wechsler tests 12, 62, 67
- white matter (WM)
 abnormalities in primary central nervous system
 lymphoma patients following treatment 193–94
 changes in breast cancer patients after chemotherapy
 25–26, 28
 demyelination 84, 148, 188
 investigation of using diffusion tensor imaging 22
 necrosis following radiation therapy 83, 91–92
 animal studies showing delayed 87
 neurological complications caused by 202
 pharmacological interventions 315–16
 radiation dose influencing 90, 150
 reduction in volume following chemotherapy and
 radiation therapy 24, 103
- whole-brain radiation therapy (WBRT) 175
 brain metastases treatment 171–72
 conflicting results of studies 175
 regulation of dose and fractionation 179
 response to 171
 primary CNS lymphoma (PCNSL) 187–88
 delayed neurotoxicity 188–89
- Women’s Health Initiative Memory Study (WHIMS)
 116–17
- work settings
 providing support in 302
 returning to work 299
- working memory
 assessment of 13, 69
 impact of chemotherapy on 27, 98
 influence of hormonal therapy 135
 psychometric tests 62, 74